Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)-Reference-Cited by-同舟云学术

Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

Published:2019-11-14 Issue:2 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Schafer Eric S.¹²^ORCID,Rau Rachel E.¹²,Berg Stacey L.¹²,Liu Xiaowei³,Minard Charles G.¹,Bishop Alexander J.R.⁴⁵,Romero J. Carolina⁴,Hicks M. John¹,Nelson Marvin D.⁶,Voss Stephan⁷^ORCID,Reid Joel M.⁸,Fox Elizabeth⁹,Weigel Brenda J.¹⁰,Blaney Susan M.¹²

Affiliation:

1. Baylor College of Medicine Houston Texas

2. Texas Children's Cancer and Hematology Centers Houston Texas

3. Children's Oncology Group Monrovia California

4. Greehey Children's Cancer Research InstituteUT Health San Antonio San Antonio Texas

5. Department of Cell Systems and AnatomyUT Health San Antonio San Antonio Texas

6. Children's Hospital of Los Angeles Los Angeles California

7. Dana Farber Cancer Institute Boston Massachusetts

8. Mayo Clinic Rochester Minnesota

9. Children's Hospital of Philadelphia Philadelphia Pennsylvania

10. University of Minnesota Minneapolis Minnesota

Publisher